Corbus Pharmaceuticals Holdings, Inc.
CRBPCorbus Pharmaceuticals Holdings, Inc. in brief
Corbus Pharmaceuticals Holdings, Inc. is a listed company in the Biotechnology industry, based in Norwood, Massachusetts, USA. It was founded in 2009. Its market value was $92 M on 20 October 2026, which makes it the 19,059th largest listed company in the world and the 3,557th largest in the USA on this site. It employs about 36 people and Yuval Cohen is its chief executive. Its shares trade under the symbol CRBP (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. is a clinical stage company focused on promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E and CRB-913, a highly peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
CRB-701 (SYS6002) is a novel clinical stage ADC that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of MMAE. In February 2023, the Company obtained a license from CSPC Megalith Biopharmaceutical Co. Ltd., a subsidiary of CSPC Pharmaceutical Group Limited, to develop and commercialize the drug in the United States, Canada, the European Union (including the European Free Trade Area), the United Kingdom and Australia. The Company is conducting a Phase 1/2 study in the U.S. and Europe enrolling patients with advanced solid tumors associated with Nectin-4 expression. The dose expansion phase of the clinical trial is ongoing. In June 2025, the Company began dosing participants in the PD-1 combination arm with CRB-701 in combination with Keytruda® (pembrolizumab). The Company has received fast track designation for CRB-701 from the U.S. Food and Drug Administration for the treatment of relapsed or refractory metastatic cervical cancer in December 2024 and in recurrent or metastatic head and neck squamous cell carcinoma previously treated with platinum-based chemotherapy and an anti-PD(L)-1 therapy in September 2025. CRB-701 is currently being investigated by CSPC in a Phase 3 clinical trial in patients with cervical cancer in China.
From the company's annual report filed with the US SEC: read the report
Corbus Pharmaceuticals Holdings, Inc. timeline
- 2009
- 🏁Founded
- 2014
- ✎Renamed Corbus Pharmaceuticals Holdings, Inc.Formerly SAV Acquisition Corp.
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2018
- •Legal Entity Identifier issuedLEI 529900MX6XCNZC7MM155 registered.
Events of Corbus Pharmaceuticals Holdings, Inc. from Wikidata, SEC EDGAR and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,757 (Jan 2020) · #3,650 (Jan 2021) · #4,689 (Jan 2022) · #5,407 (Dec 2022) · #5,026 (Jul 2023) · #4,280 (Jan 2024) · #1,832 (Mar 2026) · #3,119 (Aug 2026) · #3,432 (Oct 2026) · #3,561 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.6×
- Free cash flow yield
- -70.2%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -53.2%
- Liabilities / assets
- 12.3%
- Net debt
- $4M
- Revenue growth
- -77.7%
- R&D / revenue
- 4142.0%
- Profit per employee
- $-2.2 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-85M | $-79M | — |
| Dec 2024 | — | — | $-49M | $-40M | — |
| Dec 2023 | — | — | $-45M | $-45M | — |
| Dec 2022 | — | — | $-40M | $-42M | — |
| Dec 2021 | $1M | -77.7% | $-56M | $-46M | -5186.4% |
| Dec 2020 | $4M | — | $-123M | $-111M | -2824.1% |
| Dec 2019 | — | — | $-77M | $-71M | — |
| Dec 2018 | $5M | — | $-57M | $-56M | -1155.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-64M | $0M | $-65M | $-5.90 | — |
| Dec 2024 | $-42M | $0M | $-42M | $-3.68 | — |
| Dec 2023 | $-36M | $0M | $-36M | $-10.31 | — |
| Dec 2022 | $-38M | $0M | $-38M | $-10.15 | — |
| Dec 2021 | $-48M | $0M | $-48M | $-11.15 | — |
| Dec 2020 | $-100M | $0M | $-100M | $-1.42 | — |
| Dec 2019 | $-46M | $3M | $-48M | $-1.12 | — |
| Dec 2018 | $-30M | $2M | $-32M | $-0.98 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-38M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Oct 15, 20268-KCurrent reportRegulation FD disclosure
- Sep 14, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Jul 6, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- May 26, 20268-KCurrent reportRegulation FD disclosure · Other events
- May 21, 20268-KCurrent reportMaterial agreement · Directors or officers changed · Regulation FD disclosure
- May 14, 20268-KCurrent reportDirectors or officers changed · Shareholder vote · Regulation FD disclosure
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent reportResults of operations · Regulation FD disclosure
Official filings of Corbus Pharmaceuticals Holdings, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-85 M
- Net income
- $-79 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $168 M
- Total liabilities
- $21 M
- Total equity
- $148 M
As of December-2025
Top 100 institutional investors in Corbus Pharmaceuticals Holdings, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Cormorant Asset Management, LP | 2,344,971 | 0 (0.00%) | 11.38% | $16 M | Nov 16, 2026 |
| 2 | Ra Capital Management, L.P. | 1,914,788 | New | 9.29% | $13 M | Nov 16, 2026 |
| 3 | BlackRock, Inc. | 1,749,919 | +418,784 (+31.46%) | 8.49% | $12 M | Nov 13, 2026 |
| 4 | MPM Bioimpact LLC | 1,667,272 | New | 8.09% | $11 M | Nov 16, 2026 |
| 5 | Orbimed Advisors LLC | 1,665,656 | -71,631 (-4.12%) | 8.08% | $11 M | Nov 16, 2026 |
| 6 | Jones Hill Capital LP | 886,428 | +232,856 (+35.63%) | 4.30% | $6 M | Nov 13, 2026 |
| 7 | Sio Capital Management, LLC | 766,364 | New | 3.72% | $5 M | Nov 16, 2026 |
| 8 | Vanguard Capital Management LLC | 750,276 | -10,664 (-1.40%) | 3.64% | $5 M | Nov 13, 2026 |
| 9 | Caption Management, LLC | 474,599 | +446,747 (+1604.00%) | 2.30% | $3 M | Nov 16, 2026 |
| 10 | Geode Capital Management, LLC | 450,729 | +27,355 (+6.46%) | 2.19% | $3 M | Nov 6, 2026 |
| 11 | AQR Capital Management LLC | 335,051 | New | 1.63% | $2 M | Nov 16, 2026 |
| 12 | Marshall Wace, LLP | 308,138 | +228,807 (+288.42%) | 1.50% | $2 M | Nov 13, 2026 |
| 13 | State Street Corp | 261,626 | +6,954 (+2.73%) | 1.27% | $2 M | Nov 12, 2026 |
| 14 | Dimensional Fund Advisors LP | 210,313 | +20,099 (+10.57%) | 1.02% | $1 M | Nov 4, 2026 |
| 15 | ADAR1 Capital Management, LLC | 195,469 | -226,318 (-53.66%) | 0.95% | $1 M | Nov 16, 2026 |
| 16 | Exome Asset Management LLC | 190,714 | +5,800 (+3.14%) | 0.93% | $1 M | Nov 16, 2026 |
| 17 | Susquehanna International Group, LLP | 183,420 | -109,783 (-37.44%) | 0.89% | $1 M | Nov 16, 2026 |
| 18 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 181,102 | +29,462 (+19.43%) | 0.88% | $1 M | Nov 16, 2026 |
| 19 | Prosight Management, LP | 168,383 | -481,617 (-74.09%) | 0.82% | $1 M | Nov 13, 2026 |
| 20 | UBS Group AG | 130,052 | +81,255 (+166.52%) | 0.63% | $1 M | Nov 10, 2026 |
| 21 | Goldman Sachs Group Inc | 128,008 | +65,145 (+103.63%) | 0.62% | $1 M | Nov 16, 2026 |
| 22 | Northern Trust Corp | 127,316 | +2,410 (+1.93%) | 0.62% | $1 M | Nov 16, 2026 |
| 23 | FMR LLC | 126,922 | +118,271 (+1367.14%) | 0.62% | $1 M | Nov 10, 2026 |
| 24 | Vanguard Fiduciary Trust Co | 118,903 | +6,506 (+5.79%) | 0.58% | $1 M | Nov 13, 2026 |
| 25 | Vanguard Portfolio Management LLC | 117,622 | +6,320 (+5.68%) | 0.57% | $1 M | Nov 13, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Nuveen, LLC | 115,592 | +93,284 (+418.16%) | 0.56% | $1 M | Nov 10, 2026 |
| 27 | Susquehanna Portfolio Strategies, LLC | 97,371 | +21,392 (+28.16%) | 0.47% | $1 M | Nov 16, 2026 |
| 28 | Stonepine Capital Management, LLC | 95,000 | -330,000 (-77.65%) | 0.46% | $1 M | Nov 13, 2026 |
| 29 | Renaissance Technologies LLC | 94,900 | -15,922 (-14.37%) | 0.46% | $1 M | Nov 12, 2026 |
| 30 | Morgan Stanley | 93,085 | +72,992 (+363.27%) | 0.45% | $1 M | Nov 13, 2026 |
| 31 | Point72 Asset Management, L.P. | 89,312 | New | 0.43% | $1 M | Nov 16, 2026 |
| 32 | HSBC Holdings PLC | 87,173 | +31,949 (+57.85%) | 0.42% | $1 M | Nov 16, 2026 |
| 33 | Advisory Services Network, LLC | 85,351 | -4,600 (-5.11%) | 0.41% | $1 M | Nov 13, 2026 |
| 34 | DAFNA Capital Management LLC | 83,248 | -24,525 (-22.76%) | 0.40% | $1 M | Nov 16, 2026 |
| 35 | Millennium Management LLC | 81,269 | +69,831 (+610.52%) | 0.39% | $1 M | Nov 16, 2026 |
| 36 | XTX Topco Ltd | 79,952 | +12,298 (+18.18%) | 0.39% | $1 M | Nov 16, 2026 |
| 37 | BNP Paribas Financial Markets | 78,274 | +154 (+0.20%) | 0.38% | $1 M | Nov 12, 2026 |
| 38 | Doliver Advisors, LP | 75,975 | New | 0.37% | $1 M | Oct 1, 2026 |
| 39 | Walleye Capital LLC | 75,795 | New | 0.37% | $1 M | Nov 13, 2026 |
| 40 | Charles Schwab Investment Management Inc | 64,831 | +9,376 (+16.91%) | 0.31% | $0 M | Nov 16, 2026 |
| 41 | Rangeley Capital, LLC | 61,400 | +17,400 (+39.55%) | 0.30% | $0 M | Nov 16, 2026 |
| 42 | Verdad Advisers, LP | 60,566 | -3,037 (-4.77%) | 0.29% | $0 M | Nov 16, 2026 |
| 43 | Simplex Trading, LLC | 47,857 | New | 0.23% | $0 M | Nov 4, 2026 |
| 44 | Bank of New York Mellon Corp | 45,282 | 0 (0.00%) | 0.22% | $0 M | Nov 5, 2026 |
| 45 | D. E. Shaw & Co., Inc. | 39,502 | New | 0.19% | $0 M | Nov 16, 2026 |
| 46 | Driehaus Capital Management LLC | 38,977 | 0 (0.00%) | 0.19% | $0 M | Nov 16, 2026 |
| 47 | Panagora Asset Management Inc | 35,505 | +19,418 (+120.71%) | 0.17% | $0 M | Nov 12, 2026 |
| 48 | LMR Partners LLP | 35,500 | 0 (0.00%) | 0.17% | $0 M | Nov 16, 2026 |
| 49 | Barclays PLC | 35,144 | +27,142 (+339.19%) | 0.17% | $0 M | Nov 6, 2026 |
| 50 | Cantor Fitzgerald, L. P. | 30,000 | -50,196 (-62.59%) | 0.15% | $0 M | Nov 16, 2026 |
| 51 | Velan Capital Investment Management LP | 30,000 | +4,000 (+15.38%) | 0.15% | $0 M | Nov 16, 2026 |
| 52 | Bank Of America Corp /de/ | 29,641 | +16,387 (+123.64%) | 0.14% | $0 M | Nov 16, 2026 |
| 53 | Sectoral Asset Management Inc | 28,000 | +8,000 (+40.00%) | 0.14% | $0 M | Nov 13, 2026 |
| 54 | Pale Fire Capital SE | 27,300 | +2,999 (+12.34%) | 0.13% | $0 M | Nov 13, 2026 |
| 55 | American Century Companies Inc | 26,976 | +4,469 (+19.86%) | 0.13% | $0 M | Nov 12, 2026 |
| 56 | Engineers Gate Manager LP | 26,454 | -3,346 (-11.23%) | 0.13% | $0 M | Nov 16, 2026 |
| 57 | Price T Rowe Associates Inc /MD/ | 26,271 | 0 (0.00%) | 0.13% | $0 M | Nov 16, 2026 |
| 58 | Quadrature Capital Ltd | 20,796 | +8,597 (+70.47%) | 0.10% | $0 M | Nov 13, 2026 |
| 59 | Rhumbline Advisers | 19,742 | -721 (-3.52%) | 0.10% | $0 M | Nov 10, 2026 |
| 60 | Susquehanna Fundamental Investments, LLC | 18,852 | 0 (0.00%) | 0.09% | $0 M | Nov 16, 2026 |
| 61 | Mariner, LLC | 17,906 | +6,270 (+53.88%) | 0.09% | $0 M | Nov 12, 2026 |
| 62 | Jane Street Group, LLC | 15,537 | -123,596 (-88.83%) | 0.08% | $0 M | Nov 12, 2026 |
| 63 | Squarepoint Ops LLC | 14,218 | New | 0.07% | $0 M | Nov 9, 2026 |
| 64 | Sig Brokerage, LP | 14,200 | New | 0.07% | $0 M | Nov 16, 2026 |
| 65 | Ieq Capital, LLC | 14,037 | New | 0.07% | $0 M | Nov 10, 2026 |
| 66 | Deutsche Bank AG\ | 14,023 | -2,048 (-12.74%) | 0.07% | $0 M | Nov 6, 2026 |
| 67 | Canada Pension Plan Investment Board | 12,400 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 68 | Aigen Investment Management, LP | 10,262 | New | 0.05% | $0 M | Nov 16, 2026 |
| 69 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 9,174 | +7,950 (+649.51%) | 0.04% | $0 M | Nov 16, 2026 |
| 70 | Jpmorgan Chase & Co | 8,552 | +1,698 (+24.77%) | 0.04% | $0 M | Nov 12, 2026 |
| 71 | Vanguard Global Advisers, LLC | 8,467 | +3,772 (+80.34%) | 0.04% | $0 M | Nov 13, 2026 |
| 72 | New York State Common Retirement Fund | 6,600 | 0 (0.00%) | 0.03% | $0 M | Nov 17, 2026 |
| 73 | Police & Firemen's Retirement System of New Jersey | 5,480 | 0 (0.00%) | 0.03% | $0 M | Nov 9, 2026 |
| 74 | Citigroup Inc | 4,806 | -6,513 (-57.54%) | 0.02% | $0 M | Nov 4, 2026 |
| 75 | Royal Bank Of Canada | 4,465 | +802 (+21.89%) | 0.02% | $0 M | Nov 16, 2026 |
| 76 | Tower Research Capital LLC (TRC) | 4,319 | +3,385 (+362.42%) | 0.02% | $0 M | Nov 16, 2026 |
| 77 | Arax Advisory Partners | 3,450 | +3,447 (+114900.00%) | 0.02% | $0 M | Nov 12, 2026 |
| 78 | Wells Fargo & Company/mn | 3,387 | -10,449 (-75.52%) | 0.02% | $0 M | Nov 16, 2026 |
| 79 | Federation des caisses Desjardins du Quebec | 2,000 | New | 0.01% | $0 M | Nov 16, 2026 |
| 80 | Global Retirement Partners, LLC | 1,800 | 0 (0.00%) | 0.01% | $0 M | Nov 10, 2026 |
| 81 | Russell Investments Group, Ltd. | 1,623 | -137 (-7.78%) | 0.01% | $0 M | Nov 6, 2026 |
| 82 | Legal & General Group Plc | 1,596 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 83 | Atlantic Private Wealth, LLC | 1,500 | +1,000 (+200.00%) | 0.01% | $0 M | Nov 9, 2026 |
| 84 | Ameritas Investment Partners, Inc. | 1,494 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 85 | JTC Employer Solutions Trustee Ltd | 1,106 | 0 (0.00%) | 0.01% | $0 M | Nov 9, 2026 |
| 86 | Pinnacle Wealth Planning Services, Inc. | 949 | 0 (0.00%) | 0.00% | $0 M | Oct 27, 2026 |
| 87 | PNC Financial Services Group, Inc. | 790 | New | 0.00% | $0 M | Nov 6, 2026 |
| 88 | Versant Capital Management, Inc | 601 | 0 (0.00%) | 0.00% | $0 M | Oct 2, 2026 |
| 89 | Allworth Financial LP | 591 | New | 0.00% | $0 M | Nov 17, 2026 |
| 90 | GAMMA Investing LLC | 556 | +220 (+65.48%) | 0.00% | $0 M | Oct 8, 2026 |
| 91 | Sterling Capital Management LLC | 325 | -7 (-2.11%) | 0.00% | $0 M | Oct 22, 2026 |
| 92 | IFP Advisors, Inc | 295 | New | 0.00% | $0 M | Oct 16, 2026 |
| 93 | EverSource Wealth Advisors, LLC | 277 | +204 (+279.45%) | 0.00% | $0 M | Nov 4, 2026 |
| 94 | Osaic Holdings, Inc. | 261 | -1 (-0.38%) | 0.00% | $0 M | Nov 12, 2026 |
| 95 | Nisa Investment Advisors, LLC | 259 | -28 (-9.76%) | 0.00% | $0 M | Oct 20, 2026 |
| 96 | SJS Investment Consulting Inc. | 216 | New | 0.00% | $0 M | Oct 26, 2026 |
| 97 | Golden State Wealth Management, LLC | 198 | +125 (+171.23%) | 0.00% | $0 M | Nov 2, 2026 |
| 98 | Farther Finance Advisors, LLC | 170 | New | 0.00% | $0 M | Oct 8, 2026 |
| 99 | Parkside Financial Bank & Trust | 155 | New | 0.00% | $0 M | Oct 27, 2026 |
| 100 | Federated Hermes, Inc. | 123 | -232 (-65.35%) | 0.00% | $0 M | Nov 12, 2026 |
Mutual funds holding Corbus Pharmaceuticals Holdings, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 abrdn Healthcare Investorsabrdn Inc. | 778,031 | $7 M | 3.8% | 0.54% | no change | Jun 30, 2026 |
| 🇺🇸 abrdn Life Sciences Investorsabrdn Inc. | 543,719 | $5 M | 2.6% | 0.74% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 533,575 | $5 M | 2.6% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 406,966 | $4 M | 2.0% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 208,310 | $2 M | 1.0% | <0.01% | +17% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 179,556 | $2 M | 0.87% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 157,182 | $1 M | 0.76% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 83,288 | $1 M | 0.40% | <0.01% | −1.3% | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 58,383 | $1 M | 0.28% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 55,352 | $1 M | 0.27% | 0.03% | +34% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 39,702 | $0 M | 0.19% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 30,772 | $0 M | 0.15% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 31,546 | $0 M | 0.15% | <0.01% | +92% | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 26,811 | $0 M | 0.13% | <0.01% | −17% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 23,002 | $0 M | 0.11% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 27,193 | $0 M | 0.13% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 22,308 | $0 M | 0.11% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 23,576 | $0 M | 0.11% | <0.01% | +7.5% | May 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 20,000 | $0 M | 0.10% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 22,053 | $0 M | 0.11% | <0.01% | +46% | May 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 17,778 | $0 M | 0.09% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 17,490 | $0 M | 0.08% | <0.01% | +218% | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 12,700 | $0 M | 0.06% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc. | 12,572 | $0 M | 0.06% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 11,420 | $0 M | 0.06% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 12,746 | $0 M | 0.06% | <0.01% | +103% | May 31, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 10,512 | $0 M | 0.05% | <0.01% | +344% | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 8,618 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 8,208 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 7,783 | $0 M | 0.04% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 7,635 | $0 M | 0.04% | <0.01% | −29% | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 7,862 | $0 M | 0.04% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 6,112 | $0 M | 0.03% | <0.01% | +12% | Jul 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 4,840 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 4,840 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 4,668 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 4,734 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 4,229 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 4,000 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 3,964 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 3,744 | $0 M | 0.02% | 0.02% | +30% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 3,660 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 3,621 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 3,305 | $0 M | 0.02% | <0.01% | +121% | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC | 3,063 | $0 M | 0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds | 2,685 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 2,761 | $0 M | 0.01% | <0.01% | +16% | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 2,572 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 2,565 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 2,680 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 2,511 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 2,374 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 2,215 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 1,951 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 1,928 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 1,913 | $0 M | <0.01% | <0.01% | +6.9% | Jul 31, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 1,868 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 1,791 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 1,494 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 1,452 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 1,314 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 1,297 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 1,340 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP | 1,300 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 LVIP Dimensional U.S. Core Equity 2 FundLincoln Financial Investments Corporation | 1,173 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 1,143 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 715 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 645 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 416 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 391 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 366 | $0 M | <0.01% | <0.01% | +4.6% | Jun 30, 2026 |
| 🇺🇸 Dimensional US Vector Equity ETFDimensional Fund Advisors LP | 201 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc. | 113 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 99 | $0 M | <0.01% | <0.01% | +7.6% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 74 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Corbus Pharmaceuticals Holdings, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Cormorant Asset Management, LPFormer 10% Owner | Sellindirect | -425,000 | $4.101 | $1.7 M | 1.92 M | Form 4 |
| filed | Yong BenDirector | Sell10b5-1 plan | -2,000 | $7.840 | $16 K | 9,383 | Form 4 |
| filed | Leonardo Viana NicacioChief Medical Officer | Grant or award | +58,333 | — | — | 58,333 | Form 4 |
| filed | Nishant C. SaxenaChief Business Officer | Buy | +2,600 | $9.630 | $25 K | 77,900 | Form 4 |
| filed | Sean F. MoranChief Financial Officer | Sell10b5-1 plan | -12,000 | $10.08 | $121 K | 84,694 | Form 4 |
| filed | Yuval CohenChief Executive Officer, Director | Sell10b5-1 plan | -17,000 | $10.08 | $171 K | 157,316 | Form 4 |
| filed | Winston KungDirector | Sell10b5-1 plan | -2,026 | $7.910 | $16 K | 12,140 | Form 4 |
| filed | John Kenneth JenkinsDirector | Sell10b5-1 plan | -4,800 | $7.910 | $38 K | 3,833 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Corbus Pharmaceuticals Holdings, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 231 shares at $4.46
- : 412 shares at $4.33
- : 1,432 shares at $5.49
- : 1,407 shares at $5.78
- : 262 shares at $5.85
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Corbus Pharmaceuticals Holdings, Inc. scorecard#
Passes 3 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 20, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.6×Price to book 0.6× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-70.2%Free cash flow is -70.2% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-5.90 vs -3.68Diluted EPS -5.90 in fiscal 2025 against -3.68 the year before (report's currency).
- ✓Net income higher than five years earlier-$79 M-$79 M in fiscal 2025 against -$111 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$79 MNet income -$79 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-54.2%-54.2% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities8.1×Current ratio 8.07 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year22.0%Diluted shares up 22.0% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Corbus Pharmaceuticals Holdings, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | — | — | 0−100%— | 0.9−77.6%100% | 3.9−89.1%100% | 36+650%100% | 4.8+97.6%100% | 2.4+27.7%100% | 1.9—100% | |
| Research and development | 70+118%— | 32+3.4%— | 31r31+93.1%— | 16−55.7%— | 36−62.9%4134% | 98+9.7%2496% | 90+84.3%248% | 49+86.7%1008% | 26+68.7%1067% | 15—808% | |
| General and administrative | 15−7.8%— | 16+18.6%— | 14r14−25.6%— | 19−8.5%— | 20−28.3%2317% | 28+20.5%723% | 24+82.5%65.4% | 13+44.5%269% | 9.0+38.8%367% | 6.5—338% | |
| Operating expenses | 85+75.1%— | 49+8.1%— | 45r45+13.2%— | 40−30.0%— | 57−55.1%6450% | 127+11.9%3219% | 113+83.9%313% | 62+75.9%1277% | 35+59.9%1434% | 22—1146% | |
| Operating income | −85—— | −49—— | −45r−45—— | −40—— | −56—−6350% | −123—−3119% | −77—−213% | −57—−1177% | −33—−1334% | −20—−1046% | |
| Interest and finance income | — | — | — | — | — | — | 1.2+24.9%3.4% | 1.0—20.4% | — | — | |
| Interest expense and finance costs | 0−100%— | 1.9−51.5%— | 3.9r3.8+24.6%— | 3.1+14.3%— | 2.7+140%307% | 1.1—28.6% | 0—0.0% | — | 0.0+16.6%0.1% | 0.0—0.2% | |
| Net interest income | — | — | −2.9—— | −2.1—— | −1.8—−208% | −1.0−184%−26.1% | 1.2—3.4% | — | — | — | |
| Other non-operating income (expense) | 6.8−20.4%— | 8.5+1696%— | 0.5r0.5—— | −2.5−124%— | 10−10.3%1174% | 12+104%293% | 5.7+425%15.6% | 1.1+662%22.3% | 0.1—5.8% | −0.0—−0.7% | |
| Income tax | 0—— | 0—— | — | — | — | — | — | — | — | — | |
| Net income including minority interests | −79—— | −40—— | −45r−45—— | −42—— | −46—−5176% | −111—−2826% | — | — | — | — | |
| Minority interests' share of net income | −79—— | −40—— | — | — | — | — | — | — | — | — | |
| Net income attributable to shareholders | −79—— | −40—— | −45r−45—— | −42—— | −46—−5176% | −111—−2826% | −71—−198% | −56—−1154% | −32—−1329% | −20—−1046% | |
| Earnings per share, basic | -5.90—— | -3.68—— | -10.31—— | -10.15—— | -11.15r-0.37—— | -1.42—— | -1.12—— | -0.98—— | -0.65—— | -0.49—— | |
| Earnings per share, diluted | -5.90—— | -3.68—— | -10.31—— | -10.15—— | -11.15r-0.37—— | -1.42—— | -1.12—— | -0.98—— | -0.65—— | -0.49—— | |
| Shares, weighted average (basic) | 13+22.0%— | 11+152%— | 4.3+3.8%— | 4.2+1.8%— | 4.1r123−94.8%— | 78—— | — | — | — | — | |
| Shares, weighted average (diluted) | 13+22.0%— | 11+152%— | 4.3+3.8%— | 4.2+1.8%— | 4.1r123−94.8%— | 78+22.3%— | 64+12.1%— | 57+13.6%— | 50+22.0%— | 41—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 28+65.7%16.9% | 17+25.3%11.0% | 14r14−19.3%48.5% | 17−32.0%25.6% | 25−70.7%23.2% | 85+169%83.5% | 32−24.0%64.6% | 42−33.2%88.8% | 63+317%93.4% | 15—83.8% | |
| Short-term investments | 135+2.2%80.1% | 132+1736%84.6% | 7.2r7.2−83.0%25.4% | 42−41.9%63.6% | 73—67.4% | — | — | — | — | — | |
| Other current assets | 3.0−16.9%1.8% | 3.6+48.2%2.3% | 2.4r2.4+209%8.7% | 0.8−66.5%1.2% | 2.4−36.3%2.2% | 3.7−0.3%3.6% | 3.7+49.5%7.6% | 2.5−11.3%5.3% | 2.8+202%4.2% | 0.9—5.2% | |
| Current assets | 167+9.1%99.3% | 153+550%98.1% | 24r24−60.9%83.3% | 60−39.9%90.8% | 100+8.8%93.0% | 92+141%90.0% | 38−13.8%77.6% | 44−32.5%94.1% | 66+276%97.8% | 17—97.3% | |
| Property, plant and equipment | 0.2−58.7%0.1% | 0.4−60.4%0.2% | 1.0r1.0−39.7%3.4% | 1.6−32.6%2.4% | 2.4−41.2%2.2% | 4.1−20.0%4.0% | 5.1+87.9%10.3% | 2.7+88.8%5.8% | 1.4+229%2.1% | 0.4—2.4% | |
| Right-of-use (leased) assets | 1.1−49.3%0.6% | 2.1−30.4%1.4% | 3.1r3.1−21.1%10.8% | 3.9−15.7%5.9% | 4.6−12.2%4.3% | 5.2−9.8%5.1% | 5.8—11.8% | — | — | — | |
| Total assets | 168+7.9%100% | 156+451%100% | 28r28−57.4%100% | 66−38.4%100% | 108+5.3%100% | 102+108%100% | 49+4.6%100% | 47−29.8%100% | 67+274%100% | 18—100% | |
| Accounts payable | 2.2−53.7%1.3% | 4.8+50.6%3.1% | 3.2r3.2+46.2%11.2% | 2.2+22.0%3.3% | 1.8−75.9%1.7% | 7.4−33.5%7.2% | 11+74.8%22.6% | 6.3+103%13.5% | 3.1−8.5%4.7% | 3.4—19.1% | |
| Debt due within a year | — | — | 16+469%56.3% | 2.8−9.6%4.2% | 3.1—2.9% | — | — | — | — | — | |
| Current liabilities | 21+75.1%12.3% | 12−62.9%7.6% | 32r32+152%113% | 13−25.7%19.1% | 17−46.7%15.8% | 32−8.6%31.2% | 35+92.9%71.0% | 18+120%38.5% | 8.2−7.8%12.2% | 8.9—49.7% | |
| Long-term debt | — | — | 0−100%0.0% | 16+2.2%24.1% | 16−13.3%14.5% | 18—17.6% | — | — | — | — | |
| Lease liabilities (non-current) | 0−100%0.0% | 1.6−49.6%1.0% | 3.2r3.2−30.7%11.5% | 4.7−21.5%7.1% | 6.0−16.0%5.5% | 7.1−12.4%6.9% | 8.1+489%16.5% | 1.4—2.9% | — | — | |
| Total liabilities | 21+53.8%12.3% | 13−61.8%8.6% | 35r35+5.6%124% | 33−13.7%50.3% | 39−32.3%35.9% | 57+32.7%55.7% | 43+121%87.5% | 19+112%41.4% | 9.2+2.5%13.7% | 9.0—50.1% | |
| Retained earnings | −555—−330% | −477—−306% | −437r−437—−1545% | −392—−591% | −350—−325% | −304—−297% | −193—−392% | −121—−258% | −66—−98.1% | −33—−186% | |
| Shareholders' equity | 148+3.6%87.7% | 142—91.4% | −6.9r−6.9−121%−24.4% | 33r33−52.3%49.7% | 69+52.6%64.1% | 45+635%44.3% | 6.2−77.6%12.5% | 28−52.4%58.6% | 58+548%86.3% | 8.9—49.9% | |
| Total liabilities and equity | 168+7.9%100% | 156+451%100% | 28r28−57.4%100% | 66−38.4%100% | 108+5.3%100% | 102+108%100% | 49+4.6%100% | 47−29.8%100% | 67+274%100% | 18—100% | |
| Shares outstanding | 18+44.6%— | 12+175%— | 4.4+6.1%— | 4.2+0.0%— | 4.2r125−95.8%— | 99+52.9%— | 65+13.0%— | 57+3.0%— | 56+24.4%— | 45—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.2−60.4%— | 0.6−8.3%— | 0.6r0.6−16.0%— | 0.8−23.7%— | 1.0−11.0%113% | 1.1+52.0%28.5% | 0.7+49.7%2.0% | 0.5+93.2%10.2% | 0.3+192%10.5% | 0.1—4.6% | |
| Share-based compensation | 6.3+2.3%— | 6.1+77.1%— | 3.5r3.5−39.3%— | 5.7−39.7%— | 9.5−23.9%1075% | 12+4.0%316% | 12+57.5%33.2% | 7.6+33.6%158% | 5.7+80.0%233% | 3.2—166% | |
| Cash from operating activities | −64—— | −42—— | −36r−36—— | −38—— | −48—−5465% | −100—−2532% | −46—−126% | −30—−624% | −28—−1139% | −14—−710% | |
| Capital expenditure | −0.0—— | 0—— | 0—— | −0.0—— | −0.1—−6.1% | −0.5—−12.3% | −2.7—−7.6% | −2.3—−47.7% | −0.7—−29.0% | −0.4—−18.5% | |
| Cash from investing activities | −1.6—— | −121−440%— | 36r36+18.5%— | 30—— | −73—−8327% | −0.5—−12.3% | −2.7—−7.6% | −2.3—−47.7% | −0.7—−29.0% | −0.4—−18.5% | |
| Debt issued | — | — | — | 1.4—— | — | 19—476% | — | — | — | — | |
| Debt repaid | — | — | — | −1.5—— | — | — | — | — | — | — | |
| Shares issued | 77−57.5%— | 182+343406%— | 0.1r0.2—— | — | 63−56.0%7098% | 142+250%3612% | 41+237%113% | 12−84.7%250% | 79+372%3233% | 17—874% | |
| Cash from financing activities | 77−53.5%— | 167—— | −2.8r−2.8—— | −0.5−101%— | 61−60.7%6898% | 155+303%3934% | 38+237%106% | 11−85.0%237% | 76+354%3115% | 17—876% | |
| Change in cash | 11+225%— | 3.5—— | −3.3r−3.3—— | −8.0—— | −61−211%−6893% | 55—1389% | −10.0—−27.7% | −21−144%−434% | 48—1947% | — | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 104+71.4%— | 34+64.2%— | 31+105%— | 20+26.7%— | 18*+109%— | 21+93.0%— | 15+121%— | 16+171%— | 8.8*+25.9%— | 11—— | 6.9—— | 5.8r5.8—— | 7.0r7.0*—— | |
| General and administrative | 18+14.0%— | 4.6+28.7%— | 5.0+26.5%— | 4.5+8.5%— | 3.6*−6.8%— | 3.6−24.3%— | 4.0−3.8%— | 4.1+7.0%— | 3.8*+22.2%— | 4.7—— | 4.1—— | 3.9r3.9—— | 3.1r3.1*—— | |
| Operating expenses | 121+59.7%— | 39+59.0%— | 36+89.0%— | 24+22.9%— | 22*+74.3%— | 24+57.5%— | 19+74.3%— | 20+105%— | 13*+24.8%— | 16—— | 11—— | 9.6r9.6—— | 10r10*—— | |
| Operating income | −121—— | −39—— | −36—— | −24—— | −22*—— | −24—— | −19—— | −20—— | −13*—— | −16—— | −11—— | −9.6r−9.6—— | −10r−10*—— | |
| Interest expense and finance costs | — | — | — | — | 0*—— | 0−100%— | 0−100%— | 0−100%— | 0*−100%— | 0.4—— | 0.7—— | 0.8r0.8—— | 0.9*—— | |
| Net interest income | — | — | — | — | — | — | — | — | — | 1.2—— | 0.9—— | −0.2—— | −3.6r−0.7*—— | |
| Other non-operating income (expense) | 5.0−41.1%— | 1.1−0.5%— | 1.2−22.6%— | 1.3−52.3%— | 1.4*−54.1%— | 1.1−37.6%— | 1.5+50.4%— | 2.8+2.7%— | 3.1*+47.7%— | 1.7—— | 1.0—— | 2.7r2.7—— | 2.1r2.1*—— | |
| Net income including minority interests | −116—— | −38—— | −35—— | −23—— | −21*—— | −23—— | −18—— | −17—— | −9.5*—— | −14—— | −10.0—— | −6.9r−6.9—— | −8.0r−8.0*—— | |
| Net income attributable to shareholders | −116—— | −38—— | −35—— | −23—— | −21*—— | −23—— | −18—— | −17—— | −9.5*—— | −14—— | −10.0—— | −6.9r−6.9—— | −8.0r−8.0*—— | |
| Earnings per share, basic | — | -1.81—— | -1.81—— | -1.23—— | — | -1.90—— | -1.44—— | -1.39—— | — | -1.15—— | -0.90—— | -0.83—— | — | |
| Earnings per share, diluted | — | -1.81—— | -1.81—— | -1.23—— | — | -1.90—— | -1.44—— | -1.39—— | — | -1.15—— | -0.90—— | -0.83—— | — | |
| Shares, weighted average (basic) | 21+69.3%— | 21+69.3%— | 19+58.6%— | 19+53.3%— | — | 12+2.4%— | 12+10.7%— | 12+46.8%— | — | 12—— | 11—— | 8.3—— | — | |
| Shares, weighted average (diluted) | 21+69.3%— | 21+69.3%— | 19+58.6%— | 19+53.3%— | — | 12+2.4%— | 12+10.7%— | 12+46.8%— | — | 12—— | 11—— | 8.3—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 30—24.6% | 30+12.1%24.6% | 23+16.6%18.4% | 26+35.8%17.8% | 28+65.7%16.9% | 27+38.9%24.6% | 20−15.4%16.0% | 19+34.0%13.5% | 17+25.3%11.0% | 19—11.8% | 24—15.6% | 14—11.2% | 14r14—48.5% | |
| Short-term investments | 85—69.2% | 85+10.5%69.2% | 95−2.0%74.5% | 113−1.2%77.9% | 135+2.2%80.1% | 77−45.0%70.3% | 97−21.7%77.2% | 114+7.4%81.4% | 132+1736%84.6% | 140—85.2% | 123—81.2% | 106—84.3% | 7.2r7.2—25.4% | |
| Other current assets | 3.6—2.9% | 3.6+9.4%2.9% | 4.8−19.1%3.8% | 5.0+15.7%3.4% | 3.0−16.9%1.8% | 3.3+166%3.0% | 5.9+494%4.8% | 4.3+228%3.1% | 3.6+48.2%2.3% | 1.2—0.8% | 1.0—0.7% | 1.3—1.0% | 2.4r2.4—8.7% | |
| Current assets | 119—96.8% | 119+10.6%96.8% | 123−0.1%96.7% | 144+4.5%99.4% | 167+9.1%99.3% | 108−33.1%98.2% | 123−17.2%98.2% | 137+12.9%98.2% | 153+550%98.1% | 161—98.0% | 148—97.6% | 122—96.8% | 24r24—83.3% | |
| Property, plant and equipment | 0.0—0.0% | 0.0−82.1%0.0% | 0.1−71.7%0.1% | 0.1−61.8%0.1% | 0.2−58.7%0.1% | 0.2−61.3%0.2% | 0.3−62.6%0.2% | 0.3−63.0%0.2% | 0.4−60.4%0.2% | 0.5—0.3% | 0.7—0.4% | 0.8—0.7% | 1.0r1.0—3.4% | |
| Right-of-use (leased) assets | 3.5—2.9% | 3.5+160%2.9% | 3.8+133%3.0% | 0.8−57.6%0.6% | 1.1−49.3%0.6% | 1.4−42.9%1.2% | 1.6−37.8%1.3% | 1.9−33.8%1.3% | 2.1−30.4%1.4% | 2.4—1.4% | 2.6—1.7% | 2.8—2.3% | 3.1r3.1—10.8% | |
| Total assets | 123—100% | 123+12.2%100% | 127+1.5%100% | 144+3.3%100% | 168+7.9%100% | 110−33.3%100% | 125−17.7%100% | 140+11.3%100% | 156+451%100% | 164—100% | 152—100% | 126—100% | 28r28—100% | |
| Accounts payable | 4.1—3.3% | 4.1+48.5%3.3% | 5.3+31.7%4.1% | 0.4−89.3%0.3% | 2.2−53.7%1.3% | 2.7−5.1%2.5% | 4.0+246%3.2% | 4.1+95.4%2.9% | 4.8+50.6%3.1% | 2.9—1.8% | 1.2—0.8% | 2.1—1.7% | 3.2r3.2—11.2% | |
| Debt due within a year | — | — | — | — | — | — | — | — | — | — | — | 13—10.2% | 16—56.3% | |
| Current liabilities | 35—28.5% | 35+105%28.5% | 21+61.1%16.9% | 18+56.1%12.6% | 21+75.1%12.3% | 17+46.8%15.6% | 13−44.4%10.7% | 12−55.2%8.3% | 12−62.9%7.6% | 12—7.1% | 24—15.8% | 26—20.6% | 32r32—113% | |
| Long-term debt | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | 0—0.0% | |
| Lease liabilities (non-current) | 3.2—2.6% | 3.2+935%2.6% | 3.3+329%2.6% | — | 0−100%0.0% | 0.3−85.0%0.3% | 0.8−69.0%0.6% | 1.2−57.8%0.9% | 1.6−49.6%1.0% | 2.0—1.2% | 2.5—1.6% | 2.9—2.3% | 3.2r3.2—11.5% | |
| Total liabilities | 38—31.0% | 38+120%31.0% | 25+75.6%19.5% | 18+41.4%12.6% | 21+53.8%12.3% | 17+27.0%15.9% | 14−46.7%11.3% | 13−55.4%9.2% | 13−61.8%8.6% | 14—8.3% | 26—17.4% | 29—22.9% | 35r35—124% | |
| Retained earnings | −651—−530% | −651—−530% | −613—−483% | −578—−400% | −555—−330% | −535—−488% | −512—−409% | −494—−353% | −477—−306% | −467—−285% | −454—−298% | −444—−353% | −437r−437—−1545% | |
| Shareholders' equity | 85—69.0% | 85−8.0%69.0% | 102−7.9%80.5% | 126−0.6%87.4% | 148+3.6%87.7% | 92−38.8%84.1% | 111−11.6%88.7% | 127+31.1%90.8% | 142—91.4% | 150—91.7% | 126—82.6% | 97r97—77.1% | −6.9r−6.9—−24.4% | |
| Total liabilities and equity | 123—100% | 123+12.2%100% | 127+1.5%100% | 144+3.3%100% | 168+7.9%100% | 110−33.3%100% | 125−17.7%100% | 140+11.3%100% | 156+451%100% | 164—100% | 152—100% | 126—100% | 28r28—100% | |
| Shares outstanding | 21—— | 21+64.4%— | 19+52.4%— | 18+45.0%— | 18+44.6%— | 13+2.9%— | 12+6.6%— | 12+16.4%— | 12+175%— | 12—— | 11—— | 11—— | 4.4—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.2−37.4%— | 0.1*0.0%— | 0.1*−3.8%— | 0.0−39.5%— | 0.0*−63.4%— | 0.1*−67.1%— | 0.1*−64.7%— | 0.1−46.7%— | 0.1*−9.5%— | 0.2*—— | 0.2r0.2*—— | 0.2r0.2—— | 0.1r0.1*—— | |
| Share-based compensation | 7.0+7.2%— | 1.8+14.3%— | 1.8+15.5%— | 1.9+11.8%— | 1.4*−12.4%— | 1.6r0.0+70431%— | 1.6r0.0+121251%— | 1.7+74.5%— | 1.6*+104%— | 0.0r2.2—— | 0.0r1.3—— | 1.0r1.0—— | 0.8r0.8*—— | |
| Cash from operating activities | −92—— | −21*—— | −30*—— | −26—— | −16*—— | −16*—— | −17*—— | −16—— | −11*—— | −14*—— | −8.9r−8.9*—— | −8.0r−8.0—— | −6.0r−6.0*—— | |
| Capital expenditure | −0.0—— | −0.0*—— | −0.0*—— | −0.0—— | −0.0*—— | 0*—— | 0*—— | 0—— | — | — | — | — | 0*—— | |
| Cash from investing activities | −6.9−111%— | 9.6*−51.3%— | 18*+2.9%— | 22+23.9%— | −57*−755%— | 20*—— | 18*—— | 18—— | 8.7*−16.0%— | −15*—— | −16r−16*—— | −98r−98—— | 10r10*—— | |
| Shares issued | — | 19*+551%— | — | — | 75*—— | 2.9*−92.1%— | 0*−100%— | 0−100%— | −0.0*—— | 36*—— | 37r31*—— | 109r116—— | −0.1r0.0*—— | |
| Cash from financing activities | — | 19*+551%— | — | — | 75*—— | 2.9*−88.6%— | 0*−100%— | 0−100%— | −0.0*—— | 25*—— | 35r35*—— | 107r107—— | −1.9r−1.9*—— | |
| Change in cash | 3.0−60.6%— | 6.9*−0.9%— | −2.3*−300%— | −3.1−283%— | 1.5*—— | 6.9*—— | 1.1*−88.1%— | 1.7+349%— | −2.2*−190%— | −4.3*—— | 9.6r9.6*—— | 0.4r0.4—— | 2.5r2.5*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Corbus Pharmaceuticals Holdings, Inc. operates: 3 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 3 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters2 offices1 subsidiary | — |
| 🇦🇺 Australia | 1 subsidiary | — |
| 🇬🇧 UK | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Corbus Pharmaceuticals Holdings, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. Cohen | $3.8 M | $2.6 M | $1.8 M | $244 |
| 2024Dr. Cohen | $4.2 M | $4.1 M | $2.7 M | $354 |
| 2023Dr. Cohen | $1.1 M | $1.4 M | $779 K | $181 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Corbus Pharmaceuticals Holdings, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 7 · Material agreement 3 · Shareholder vote 2 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officersMaterial agreement | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Lobbying by Corbus Pharmaceuticals Holdings, Inc.#
$146 K spent on lobbying the US Congress and federal agencies in 2020, most often on health issues.
- Health Issues4 reports
Lobbying firms hired in 2020
East End Group, LLC $146 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2020 | $146 K | — | 4 |
| 2019 | $180 K | — | 4 |
| 2018 | $60 K | — | 2 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Corbus Pharmaceuticals Holdings, Inc”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Corbus Pharmaceuticals Holdings, Inc.#
3 labor condition applications certified in fiscal 2022 for 3 positions, at a median wage of $96 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Scientist IChemists | 3 | $96 K |
Where: Norwood, MA 3
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2022 | 3 | 3 | $96 K | 3 |
| FY2020 | 1 | 1 | $110 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Corbus Pharmaceuticals, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020 | · | · | · | · | · | · | · | · | · | 89 | · | · | 89 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 89 people (54% of workforce) | Restructuring planSEC 8-K | “Under this plan, the Company plans to reduce its 2020 workforce by 54%, including 89 employees that will be terminated, resulting in a workforce of 76 employees.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Corbus Pharmaceuticals Holdings, Inc. compares in Biotechnology
- Market cap$92 M · higher than 35% of 726
- Revenue growth-77.7% · higher than 7% of 438
- Price / book0.6× · lower than 89% of 534
- FCF yield-70.2% · higher than 17% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc.🇺🇸 | $92 M | — | — | -77.7% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 20, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, Wikidata, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Corbus Pharmaceuticals Holdings, Inc.? Verify and update this profile — free
Show Corbus Pharmaceuticals Holdings, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.